Trial Profile

The PuMP Trial: "A Multistage Phase 1 Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of the Oncolytic HSV1 MVR-C5252 in Patients With Recurrent High-Grade Glioma"

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 03 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

30 Apr 2025 Results (n=5) assessing safety, tolerability, and preliminary efficacy of MVR-C5252 delivered intratumorally via convection-enhanced delivery (CED), bypassing the blood-brain barrier, presented at the 116th Annual Meeting of the American Association for Cancer Research.
27 Apr 2025 Results presented in the Immvira Pharma Media Release.
27 Apr 2025 According to an Immvira Pharma media release, the company presented the Phase I clinical results at American Association for Cancer Research ("AACR") annual meeting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com